

An evidence summary for health regulators and practitioners

The health effects of vaping

INTRODUCTION

In recent years health practitioners, public health officials and the public have been provided with inconsistent and contradictory information about the health consequences of using e-cigarettes. This fact sheet is intended to present information on some of the key health concerns.


Many people have heard that vaping is “95% less harmful” than smoking. This is an estimate that has been promoted by Public Health England since 2015 and which is based on a report it commissioned from a panel of scientists. (1,2,3) The relative risk of “95% less harmful” emerged from the pooled opinions of the scientists involved in the review, and not by using conventional scientific methods of comparing risk. As a result, many other researchers have expressed concerns about the appropriateness of the methods and the validity of the statement. (4,5) Even the panel which developed it acknowledged that “the lack of hard evidence for the harms of most products on most of the criteria” limited their conclusions. (3) Public Health England continues to encourage smokers to consider using e-cigarettes as a quitting aid. (6)

Other scientific panels have declined to suggest that e-cigarettes are considerably safer, let alone 95% safer. One of these was a review commissioned by the U.S. Food and Drug Administration and conducted by the United States National Academies of Science, Engineering and Medicine (NASEM). Like the Public Health England report, this was authored by a panel of independent scientists who reviewed the available scientific literature, including the evidence considered by the English panel. These American researchers, however, came to a very different series of conclusions in their 2018 report. (7) Considered together, their 47 conclusions (including 26 on health effects) would lead one to take a precautionary approach towards e-cigarette regulation. The U.S. Centers for Disease Control and Prevention and other federal agencies do not encourage the use of e-cigarettes.

The evidence reviewed by both these panels is now at least 2 years old, and many subsequent studies have now been reported. With increasing evidence about their long- and short-term health effects, e-cigarettes remain a concern for public health.



Public Health England (6)



U.S. Centers for Disease Control and Prevention. (67)

Physicians *for a* Smoke-Free Canada

134 Caroline Avenue ♦ Ottawa ♦ Ontario ♦ K1Y 0S9
www.smoke-free.ca ♦ psc@smoke-free.ca

E-CIGARETTES AND HEART DISEASE AND STROKE

Although the 2018 review by the National Academies of Science, Engineering and Medicine found there was “no evidence” available to assess the impact of electronic cigarette smoking on increased cardiac risks, (7) subsequent studies have provided evidence to support conclusions that these products increase the risks of heart disease and stroke.

Researchers in Ohio recently reviewed preclinical and clinical studies on e-cigarettes and considered what these results could mean for long-term risks to cardiovascular health. In their Figure 1, they identified three separate routes by which e-cigarettes could increase the risk of cardiovascular disease: the impact of nicotine, the effect of particulate matter and metals, and the impact of flavours and solvents used in vaping liquids. (8) They concluded:




Figure 1 from Buchanan et al (8)

“The studies presented in this review have shown that e-cigarettes can induce negative cardiovascular effects through various mechanisms such as oxidative stress, inflammation, DNA damage, arterial stiffness, and altered haemodynamics and platelet activity. Individually and in combination with one another, these effects suggest pathways that chronic e-cigarette use could increase the development of CVD.” (8)

The risks from ultrafine particles in e-cigarettes

E-cigarette vapour produces ultrafine particles, as small or smaller than those produced by conventional cigarettes as shown in Figure 2. (9) These ultrafine particles carry nicotine deep into the lungs, triggering inflammatory processes that lead to cardiovascular disease. E-cigarettes damage the vascular endothelium, thereby inhibiting the ability of arteries to dilate in response to increased blood flow. (10,11) E-cigarette aerosol harms important blood processes (including activation, aggregation and adhesion of platelets). (12,13) These and other adverse biological changes to the cardiovascular system are not diseases in and of themselves. They are biological changes that are mostly reversible – provided one quits vaping. However, many vapers are addicted to nicotine. Consequently, repeated vaping over years and decades increases the risk of heart disease and stroke from e-cigarettes. (14,15,16,17,18,19)




Figure 2: E-cigarettes produce smaller ultrafine particles than cigarettes do.

Particle number distribution from (a) mainstream aerosol in e-liquid and from (b) conventional cigarette as a function of particle size (diameter, D) (9)

The higher risks of dual use of electronic and combustible cigarettes

Dual use of both e-cigarettes and conventional cigarettes is the most common form of e-cigarette consumption. Dual use increases the risk of heart disease compared to exclusive use of one product or the other. (14,16,20) One recent cross-sectional analysis examined the relationship between e-cigarette use, cigarette use and the risk of heart attack in the United States. (16) Risk, as measured by the adjusted odd ratio, was similar, whether one used e-cigarettes or e-cigarettes. Risk was considerably elevated for dual users, as shown in Table 1.

Table 1: Adjusted odds ratio for myocardial infarction (16)

E-cigarette use		Cigarette use		Dual use, e-cigarettes & cigarettes	
Never	Reference	Never	Reference	Never	Reference
Former	1.25	Former	1.48	All dual use	6.64
Some day	1.99	Some day	2.38		
Every day	2.25	Every day	2.95		


E-CIGARETTES AND LUNG DISEASES

Acute lung disease

In August 2019, cases of acute lung disease linked to vaping began to be reported in the United States. The number of documented cases now number in the thousands and dozens of deaths have been reported, (21) as have a few cases in Canada. (22) The only common factor in all cases is vaping, whether nicotine, cannabis or both.

Some mechanisms have been suggested by which e-cigarettes could be implicated in acute and chronic respiratory disease.

- **Mouse studies link e-cigarettes with fat deposits in the lung.** A recent study of the effect of unflavoured e-cigarette vapour, with or without nicotine, on mouse lungs showed that fat globules built up in the mouse lungs. (23) Fat deposits in human lungs are also characteristic of the recent outbreak of acute lung disease in human e-cigarette users.
- **Inhaling propylene glycol and vegetable glycerin may harm the lungs.** 50% to 90% of e-liquid is made up of propylene glycol and vegetable glycerin. These substances have a long history of safe use in industrial applications, food and cosmetics. However, it has also been long known that they were never meant to be inhaled and cause respiratory irritation when inhaled accidentally. Propylene glycol is present in cigarette smoke and about 90% of it is transformed when burned into a variety of chemicals, including carcinogens. Less of it is transformed when it is heated, aerosolized and repeatedly inhaled in e-cigarettes. A recent report concluded that “heating propylene glycol and vegetable glycerin in e-cigarettes produces lung disease hazards not previously observed in cigarette smokers.” (24)
- **E-cigarettes could trigger biological changes to the respiratory system that lead to chronic lung disease.** E-cigarette vapour damages the epithelial cells that line airways, thereby interfering with their normal healthy functioning. (25,26,27)



Other respiratory disorders

E-cigarette vapour also causes several other physiological changes that compromise the normal, healthy functioning of airways and lungs. (12,25,28) Consistent with these observations of biological changes as a result of exposure to e-cigarette aerosol, e-cigarette use also increases the risk of chronic obstructive pulmonary disease and other respiratory diseases. (29,30,31) Like the risk of heart disease, dual use of e-cigarettes and combustible cigarettes further increases the risk of lung disease compared to exclusive use of one product or the other. One longitudinal study found an odds ratio of 1.24, 2.68 and 3.3, for respiratory

diseases for current e-cigarette users, current cigarette smokers and dual users, respectively, compared to never users of e-cigarettes or tobacco. (31) Decades of observation of the dangers of cigarette use has shown that cardiovascular diseases, related metabolic diseases and lung diseases account for two-thirds of deaths caused by smoking. (32) The weight of available evidence indicates that, compared to combustible cigarette use, using e-cigarettes does not reduce the risk of cardiovascular diseases or lung diseases. Most e-cigarette users are dual users and for these people use of e-cigarettes increases the risk of cardiovascular and lung diseases.

A comprehensive review of the respiratory effects of e-cigarettes

A comprehensive review of the respiratory effects of e-cigarettes was recently published. (33) Among the over 100 studies reviewed were some which showed measurable adverse biologic effects on organ and cellular health in humans, in animals, and in vitro. The authors concluded that current knowledge of the population health effects of e-cigarettes is insufficient to determine whether the respiratory health effects of e-cigarette are less than those of combustible tobacco products.

CANCER

Many people believe that the fact that e-cigarettes have fewer carcinogens than cigarettes makes them safer. While fewer cancers may result from vaping than from smoking cigarettes, the risk of cancer is not necessarily reduced in lockstep with the reduction in numbers and amounts of carcinogens. There is no safe level of exposure to carcinogens. (34)

Nor does reducing carcinogens necessarily reduce risk from other diseases, like heart disease, stroke and lung diseases – the diseases that account for two-thirds of smoking-related deaths. (32)

There is evidence associating e-cigarettes with cancer risks. This includes research findings that:

- E-cigarette aerosol contains carcinogens that damage DNA. (35)
- E-cigarettes marketed in Canada produce carcinogenic emissions, including benzene. (36)
- E-cigarettes deregulate genes associated with cancer. (37)
- E-cigarettes deliver large amounts of nicotine. While not a carcinogen itself, nicotine speeds growth of cancerous tumours. (38)
- E-cigarette vapour induces cancer in mice. (39)

While there are as yet no studies demonstrating increased risk of cancer in e-cigarette users, the biological evidence suggests very strongly that such

U.S. Deaths from Smoking, 1965-2014




Figure 3: U.S. Surgeon General, 2014 (32)
Between 1965 and 2015, active and passive smoking killed 21 million people in the United States. Although most discussion of smoking and disease focuses on cancer, cardiovascular disease and metabolic and noncancer pulmonary disease kill most smokers.

evidence will appear when more people engage in prolonged use of e-cigarettes over many years. Dual users can also be expected to be at greater risk.

ADVERSE PREGNANCY OUTCOMES

Major health authorities and scientists recommend that pregnant women be advised to not use e-cigarettes. The US Office on Smoking and Health accepts that “prenatal nicotine exposure contributes substantially to adverse health outcomes in infants,” and cautions that “tolerating acceptance of electronic cigarette use among pregnant smokers as part of a broader public health strategy to reduce smoking puts this population at great risk.” (40) In 2016, the U.S. Surgeon General concluded that “nicotine can cross the placenta and has known effects on fetal and postnatal development. Therefore, nicotine delivered by e-cigarettes during pregnancy can result in multiple adverse consequences, including sudden infant death syndrome.” (41) Subsequently, other researchers have concluded that pregnant women should be cautioned against using e-cigarettes. (42,43,44,45,46,47,48)

Vaping products are generally recommended against as cessation methods during pregnancy. Earlier this year, the American College of Protective Medicine issued a practice statement in which it advised that “Clinicians should screen pregnant women for the use of ENDS as part of tobacco screening. Those who smoke or vape should be advised to quit all nicotine products and provided with evidence-based tobacco cessation interventions including behavioral interventions and financial incentives,” and “Clinicians should advise pregnant women who smoke cigarettes to use evidence-based treatments (e.g., behavioral counseling and financial incentives) rather than recommending ENDS.” (49)

In its 2018 report, the National Academy of Science in Medicine concluded that there was insufficient evidence to conclude whether or not e-cigarette use affects fetal development, but did not conclude that there was sufficient evidence that nicotine or vaping did not adversely affect pregnancy outcomes. (7)

HEALTH RISKS FOR YOUNG PERSONS

In 2016, the U.S. Surgeon General produced a report on e-cigarette use among youth and young adults, (41) and concluded that “Nicotine exposure during adolescence can cause addiction and can harm the developing adolescent brain.”

The U.S. Centers for Disease Control and Prevention is blunt in its assessment of the risks of e-cigarettes to young people. (50)

- “The use of e-cigarettes is unsafe for kids, teens, and young adults.”
- “Using nicotine in adolescence can harm the parts of the brain that control attention, learning, mood, and impulse control. “
- “Each time a new memory is created, or a new skill is learned, stronger connections – or synapses – are built between brain cells. Young people’s brains build synapses faster than adult brains. Nicotine changes the way these synapses are formed.”
- “Using nicotine in adolescence may also increase risk for future addiction to other drugs.”
- “Young people who use e-cigarettes may be more likely to smoke cigarettes in the future.”

Youth vaping leads to heavier cigarette smoking

The impact of e-cigarette use by children on their later use of combustible cigarettes has been studied in multiple ways. Among significant findings are:

- Youth who started on e-cigarettes were four times more likely to go on to become cigarette smokers. (51)
- “Use of e-cigarettes by US young adults, most of which is not intended to help reduce smoking, is related to more rather than less frequent and intensive cigarette smoking.” (52)
- Youth who vape misperceive the powerfully addictive nature of nicotine and are unaware of the increased risk they face for a lifetime of nicotine addiction and cigarette use. (53,54,55)

RISKS TO SUCCESSFUL SMOKING CESSATION

Smoking cigarettes is a very hard addiction to overcome, and most quit attempts result in failure. A great many studies over many years have assessed the effectiveness of different medicines, behavioural supports or other interventions at helping smokers successfully quit. In its most recent *Report on the Global Tobacco Epidemic*, the World Health Organization called for greater efforts to support smokers quitting and identified several pharmacological and behavioural interventions proven to be effective. The WHO reviewed recent evidence of the impact of e-cigarettes to smoking cessation and concluded “there is insufficient independent evidence to support the use of these products as a population-level tobacco cessation intervention to help people quit conventional tobacco use.” (56)

One of the studies reviewed by the WHO was a much-publicized randomized control trial (RCT) of e-cigarettes as a quitting device, which found that 18% of e-cigarette users has successfully quit smoking after one year compared with 9.9% of those which used conventional stop-smoking medications. (57) The WHO found “several limitations” with this study, and other researchers have similarly urged caution in interpreting its results, (58,59,60), including Canadian experts. (61) A 2018 Ontario government review concluded that “recent evidence from RCTs and observational studies do not provide support for e-cigarettes as an effective cessation aid.” (62) A 2019 review of the evidence on e-cigarettes as effective smoking cessation aids by Ontario tobacco experts found the evidence to be “inconclusive.” (63)

Outside of the clinical trial environment, the impact of e-cigarettes can be assessed in the real-world settings in which smokers live and are trying to quit. Studies of the effects of e-cigarette use on the quit attempts of smokers in real life are not encouraging. One Canadian study found that e-cigarette use was negatively associated with smoking cessation. Furthermore, e-cigarette use lessened the effectiveness of smoking cessation treatment using NRT. (64) A meta-analysis of 37 mostly real-world studies showed that, overall, users of e-cigarettes were less likely to quit smoking. (65)

A major concern with the use of e-cigarettes as cessation devices is that even those who successfully stop smoking cigarettes continue to vape. In the recent RCT of e-cigarettes cited above, 80% of former smokers were still using e-cigarettes with addictive levels of nicotine after one year. (57) Data from this same study shows that NRT was much more effective at ending any form of nicotine use - 7% of those using NRT to quit smoking succeeded in quitting all nicotine use after one year, while only 3.2% of those using e-cigarettes to quit smoking successfully abandoned all nicotine use after one year. (66)

For most people, use of vaping products decreases the likelihood of successful smoking cessation and carries substantial risk for prolonged addiction to nicotine.

WHAT STANDARD OF PROOF IS REQUIRED FOR PUBLIC HEALTH ACTION?

Most of the epidemiological studies of heart disease and lung disease reviewed here (14,15,16,17,29,30) are cross-sectional in nature. As such, they offer contributory evidence, but not proof, of causal relationships. However, they are all consistent with the biological evidence that e-cigarettes are associated with adverse changes to the cardiovascular and respiratory systems. Based on biological evidence and epidemiological evidence from cross-sectional studies and one longitudinal study, (31) e-cigarettes are properly described as risk factors for cardiovascular disease and chronic lung disease. While research should continue to achieve better understanding of the relationship of e-cigarettes to heart disease and lung disease, enough is known to take public health action now to better limit the access of non-smokers to e-cigarettes. Waiting for more proof from longitudinal studies on humans before taking public health action would be irresponsible. Longitudinal studies of e-cigarette users, while scientifically elegant, do require a number of people to become sick and die in order to create data points.

SUMMARY OF HEALTH EFFECTS OF VAPING

- Vaping products are associated with acute lung disease. They have resulted in cases numbering in the thousands and dozens of deaths in the United States. There are also a few cases in Canada. The causal pathway or pathways from vaping to acute lung disease is not yet known.
- Vaping products are addictive. This is particularly problematic for non-smokers and never smokers who take up vaping.
- Vaping products increase the risk of cardiovascular diseases.
- Vaping products increase the risk of lung diseases.
- Vaping products adversely affect memory and concentration
- Vaping product adversely affect adolescent brain development, attention, mood, learning and impulse control.
- Vaping products adversely affect pregnancy outcomes.
- Adolescents who initiate nicotine addiction on vaping devices are more likely than others to become cigarette smokers.
- Dual use of vaping products and combustible cigarettes increases the risk of cardiovascular and lung disease compared to exclusive use of either product.
- Vaping products are not effective smoking cessation devices for most smokers. For most smokers, vaping lowers the likelihood of successful quitting.

REFERENCES

1. Public Health England. E-cigarettes: an evidence update. A report commissioned by Public Health England. Public Health England; 2015.
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/733022/E-cigarettes_an_evidence_update_A_report_commissioned_by_Public_Health_England_FINAL.pdf.
2. McNeill A, Brose L, Calder R, Bauld L, Robson D. Evidence review of e-cigarettes and heated tobacco products 2018.
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/684963/Evidence_review_of_e-cigarettes_and_heated_tobacco_products_2018.pdf.
3. Nutt D, Phillips L, Balfour D, et al. Estimating the harms of nicotine-containing products using the MCDA approach. *Eur. Addict. Res.* 2014; 20: p. 218-225.
https://researchbank.acu.edu.au/cgi/viewcontent.cgi?article=9013&context=fhs_pub.
4. McKee M, Daube M, Chapman S. E-cigarettes should be regulated. *Medical Journal of Australia.* 2016 May 16; 204(9): p. 331-332.e1. <https://www.mja.com.au/journal/2016/204/9/e-cigarettes-should-be-regulated>.
5. McKee M, Capewell S. Evidence about electronic cigarettes: a foundation built on rock or sand? <https://pdfs.semanticscholar.org/be89/7d3d5b365a5ec38f6bc20566c8f320f690bd.pdf>. *British Medical Journal.* 2015 September 15; 351; h4863.
6. Public Health England. Vaping and lung disease in the US: PHE's advice. 2019 October 29.
<https://publichealthmatters.blog.gov.uk/2019/10/29/vaping-and-lung-disease-in-the-us-phes-advice/>.
7. National Academies of Sciences, Engineering, and Medicine. Public health consequences of e-cigarettes Washington: National Academies Press <https://doi.org/10.17226/24952>; 2018.
8. Buchanan N, Grimmer J, Tanwar V, Schwieterman N, Mohler P, Wold L. Cardiovascular risk of electronic cigarettes: a review of preclinical and clinical studies. *Cardiovascular research.* 2019 Oct 4. <https://academic.oup.com/cvr/advance-article/doi/10.1093/cvr/cvz256/5613736>.
9. Fuoco F, Buonanno G, Stabile L, Vigo P. Influential parameters on particle concentration and size distribution in the mainstream of e-cigarettes. *Environ. Pollut.* 2014; 184: p. 523-529.
<https://www.ncbi.nlm.nih.gov/pubmed/24172659>.
10. Lee W, Zhou Y, Ong S, Tian L, Baker N, Bae H, et al. Assessing cardiovascular risks associated with e-cigarettes with human induced pluripotent stem cell-derived endothelial cells. In Society for Research on Nicotine and Tobacco 25th Anniversary Abstracts Abstract # PA15-4; 2019; San Francisco. https://cdn.ymaws.com/www.srnt.org/resource/resmgr/SRNT19_Abstracts.pdf.
11. Mohammadi L, Derakhshandeh R, Han D, Huang A, Whitlatch A, Schick S. Relative endothelial toxicity of tobacco smoke and e-cigarette aerosol: a functional and mechanistical assessment. In Society for Research on Nicotine and Tobacco 25th Anniversary Abstracts Abstract # PA15-24; 2019; San Francisco.
https://cdn.ymaws.com/www.srnt.org/resource/resmgr/SRNT19_Abstracts.pdf.

12. Glantz S, Bareham D. E-cigarettes: use, effects on smoking, risks, and policy implications. *Annu Rev Public Health*. 2018; 39: p. 215-235. <https://www.annualreviews.org/doi/pdf/10.1146/annurev-publhealth-040617-013757>.
13. Karim Z, Hernandez K, Rivera J, Khasawneh F, Alshbool F. In utero exposure to e-cigarettes modulates platelet function and increases the risk of thrombogenesis, in mice. In Society for Research on Nicotine and Tobacco 25th Anniversary Abstracts Abstract # PA15-1; 2019; San Francisco. https://cdn.ymaws.com/www.srnt.org/resource/resmgr/SRNT19_Abstracts.pdf.
14. Alzahrani T, Pena I, Temesgen N, Glantz S. Association between electronic cigarette use and myocardial infarction. *American Journal of Preventive Medicine*. 2018 October; 55(4): p. 455-461. <https://doi.org/10.1016/j.amepre.2018.05.004>.
15. Ndunda P, Muutu T. Electronic cigarette use is associated with a higher risk of stroke. *International Stroke Conference 2019 Oral Abstracts*. Abstract 9. *Stroke*. 2019; 50(Supplement 1.9). https://www.ahajournals.org/doi/10.1161/str.50.suppl_1.9.
16. Bhatta D, Glantz S. Electronic cigarette use and myocardial infarction among adults in the United States Population Assessment of Tobacco and Health. *Journal of the American Heart Association*. 2019. <https://www.ahajournals.org/doi/pdf/10.1161/JAHA.119.012317>.
17. Middlekauff H. Cardiovascular impact of electronic cigarette use. *Trends in Cardiovascular Medicine*. 2019. <https://doi.org/10.1016/j.tcm.2019.04.006>.
18. Manderski M, Singh B, Delnevo C. E-cigarette use and myocardial infarction: Importance of a sound evidence base in the e-cigarette risks-benefits debate. *American Journal of Preventive Medicine*. 2019. <https://doi.org/10.1016/j.amepre.2019.03.012>.
19. Alzahrani T, Glantz S. Adding data from 2015 strengthens the association between e-cigarette use and myocardial infarction. *American Journal of Preventive Medicine*. 2019. <https://doi.org/10.1016/j.amepre.2019.03.008>.
20. Heart and Stroke Foundation of Canada. E-cigarettes in Canada. [Online]; 2019. Available from: <https://www.heartandstroke.ca/-/media/pdf-files/position-statements/ecigarettesincanada.ashx?rev=4bea8e80452e418195d4d726e5f8547d&hash=C8388925B2D415D78AB62924E755DC36> .
21. The U.S. Centers of Disease Control. Outbreak of Lung Injury Associated with E-Cigarette Use, or Vaping. 2019-10-11. https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html. [Online]; 2019 [cited 2019 10 23].
22. Health Canada. Severe lung illness related to vaping. [Online]; 2019. Available from: <https://www.canada.ca/en/public-health/services/diseases/vaping-pulmonary-illness.html> .
23. Madison M, Landers C, Gu B, et al. Electronic cigarettes disrupt lung lipid homeostasis and innate immunity independent of nicotine. *J Clin Invest*. 2019 Sep 4. pii: 128531. <https://www.jci.org/articles/view/128531/pdf>.
24. Physicians for a Smoke-Free Canada. Vaping, propylene glycol and vegetable glycerin. [Online]; 2019. Available from: <http://smoke-free.ca/suap/2019/propylene-glycol-and-vegetable-glycerin-and-vaping-oct2019.pdf>.

25. Chun L, Moazad F, Calfee C, Matthay M, Gotts J. Pulmonary toxicity of e-cigarettes. *American Journal of Physiology: Lung Cell Molecular Physiology*. 2017 May; 313: p. L193-L206. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582932/>.
26. Ghosh A, Coakley R, Mascenik T, Rowell T, Davis E, Rogers K. Chronic e-cigarette exposure alters the human bronchial epithelial proteome. *AJRCCM*. 2018 February. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034122/>.
27. Jabba S, Caceres A, Erythropel H, Zimmerman J, Jordt S. Flavor solvent adducts in electronic cigarette liquids are modulators of respiratory irritant receptors and cytotoxic to human lung epithelial cells. In *Society for Research on Nicotine and Tobacco 25th Anniversary Abstracts Abstract # PA45-2*; 2019; San Francisco. https://cdn.ymaws.com/www.srnt.org/resource/resmgr/SRNT19_Abstracts.pdf.
28. Ghosh A, Coakley R, Davis E, Ghio A, Muhlebach M, Esther C. E-cigarette use causes enhanced lung protease levels. In *Society for Research on Nicotine and Tobacco 25th Anniversary Abstracts Abstract # PA4-1*; 2019; San Francisco. https://cdn.ymaws.com/www.srnt.org/resource/resmgr/SRNT19_Abstracts.pdf.
29. Perez M, Atuegwu E, Oncken C, Mortensen E. E-cigarette use is associated with emphysema, chronic bronchitis and COPD. In *American Thoracic Society International Conference Abstract #A6245/402*; 2018; San Diego. https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2018.197.1_MeetingAbstracts.A6245.
30. Wills T, Pagano I, Williams R, Tam E. E-cigarette use and respiratory disorder in an adult sample. *Drug and Alcohol Dependence*. 2019; 194: p. 363-370. <https://www.sciencedirect.com/science/article/pii/S0376871618307622?via%3Dihub>.
31. Bhatta D, Glantz S. Electronic cigarette use is associated with respiratory disease among adults in the United States Population Assessment of Tobacco and Health: a longitudinal analysis. In *Society for Research on Nicotine and Tobacco 25th Anniversary Abstracts Abstract # POS2-146*; 2019; San Francisco. https://cdn.ymaws.com/www.srnt.org/resource/resmgr/SRNT19_Abstracts.pdf
32. US Department of Health and Human Services. *The Health Consequences of Smoking - 50 years of progress. A report of Surgeon General Rockville: US DHHS, Public Health Service, Office of the Surgeon General*; 2014. https://www.ncbi.nlm.nih.gov/books/NBK179276/pdf/Bookshelf_NBK179276.pdf.
33. Gotts J, Jordt S, McConnell R, Tarran R. What are the respiratory effects of e-cigarettes? *British Medical Journal*. 2019. <http://dx.doi.org/10.1136/bmj.l5275>.
34. The United States National Institute for Occupational Safety and Health. *NIOSH Evaluation of its cancer and REL policies*. [Online]; 2017. Available from: <https://www.cdc.gov/niosh/topics/cancer/policy.html>.
35. Lee HW, Park SH, Weng MW, Wang HT, Huang WC, Lepor XR, et al. E-cigarette smoke damages DNA and reduces repair activity in mouse lung, heart, and bladder as well as in human lung and bladder cells. *PNAS*. 2018 January 29. <https://www.pnas.org/content/115/7/E1560>.

36. Pankow J, Kim K, McWhirter K, Luo W, Escobedo J, Strongin R, et al. Benzene formation in electronic cigarettes. PLOS One. 2017-03-08.
<https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0173055&type=printable>.
37. Tommasi S, Caliri A, Caceres A, Moreno D, Meng L, Chen Y. Deregulation of biologically significant genes and associated molecular pathways in the oral epithelium of electronic cigarette users. International Journal of Molecular Sciences 2019 February; 20: p. 738.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386888/>.
38. Heeschen C, Jang J, Weis M, Pathak A, Kaji S. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat. Med. 2001; 7: p. 833-839.
https://www.nature.com/articles/nm0701_833.
39. Tang M, Wu X, Lee H, Xia Y, Deng F, Moreira A, et al. Electronic cigarette smoke induces lung adenocarcinoma and bladder urothelial hyperplasia in mice. PNAS. 2019.
<https://www.pnas.org/content/116/43/21727>.
40. England L, Bunnell R, Pechacek T, Tong V, McAfee T. Nicotine and the Developing Human: A Neglected Element in the Electronic Cigarette Debate. American Journal of Preventive Medicine. 2015 August; 49(2): p. 286-293. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4594223/>.
41. US Department of Health and Human Services. E-Cigarette Use Among Youth and Young Adults. A Report of the Surgeon General Atlanta : U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2016
https://www.cdc.gov/tobacco/data_statistics/sgr/e-cigarettes/index.htm.
42. Breland A, McCubbin A, Ashford K. Electronic nicotine delivery systems and pregnancy: Recent research on perceptions, cessation, and toxicant delivery. Birth Defects Research. 2019 July.
<https://onlinelibrary.wiley.com/doi/full/10.1002/bdr2.1561>.
43. Suter M, Mastrobattista J, Sachs M, Aagaard K. Is There Evidence for Potential Harm of Electronic Cigarette Use in Pregnancy? Birth Defects Research. 2015 March; 103(3): p. 186-195.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830434/>.
44. Beeza-Loya S, Viswanath H, Carter A, et al. Perceptions about e-cigarette safety may lead to e-smoking during pregnancy. Bull Menninger Clin. 2014; 78(3): p. 243-252. doi: 10.1521/bumc.2014.78.3.243. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4458373>.
45. McCubbin A, Fallin-Bennett A, Barnett J, Ashford K. Perceptions and use of electronic cigarettes in pregnancy. Health Education Research. 2017 February: p. 22-32. doi: 10.1093/her/cyw059.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914445/>.
46. Whittington J, Simmons P, Philips A, et al. The Use of Electronic Cigarettes in Pregnancy: A Review of the Literature. Obstet Gynecol Surv. 2018 September; 73(9): p. 544-549. doi: 10.1097/OGX.0000000000000595. <https://www.ncbi.nlm.nih.gov/pubmed/30265741>.
47. Orzabal M, Ramadoss J. Impact of Electronic Cigarette Aerosols on Pregnancy and Early Development. Curr Opin Toxicol. 2019 April; 14: p. 14-20. doi: 10.1016/j.cotox.2019.05.001.
<https://www.ncbi.nlm.nih.gov/pubmed/31214660>.

48. Li G, Saad S, Oliver B, Chen H. Heat or Burn? Impacts of Intrauterine Tobacco Smoke and E-Cigarette Vapor Exposure on the Offspring's Health Outcome. *Toxics*. 2018 September. doi: 10.3390/toxics6030043. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160993/>.
49. Livingston C, Freeman R, Costales V, Westhoff J, Caplan L, Sherin K, et al. Electronic Nicotine Delivery Systems or E-cigarettes: American College of Preventive Medicine's Practice Statement. *American Journal of Preventive Medicine* 2019 January; 56(1): p. 167-178. <https://doi.org/10.1016/j.amepre.2018.09.010>.
50. US Centers for Disease Control. Quick Facts on the Risks of E-cigarettes for Kids, Teens, and Young Adults. [Online]. [cited 2019 09 05. Available from: https://www.cdc.gov/tobacco/basic_information/e-cigarettes/Quick-Facts-on-the-Risks-of-E-cigarettes-for-Kids-Teens-and-Young-Adults.html].
51. Berry K, Fetterman J, Benjamin E, et al. Association of electronic cigarette use with subsequent initiation of tobacco cigarettes in US youths. *JAMA Network Open* 2019; 2(2): p. e187794. doi:10.1001/jamanetworkopen.2018.7794. <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2723425>.
52. Olfson M, Wall M, Lio SM, Sultan R, Blanco C. E-cigarette use among young adults in the US. *American Journal of Preventive Medicine*. 2019 May; 56(5): p. 655-663. [https://www.ajpmonline.org/article/S0749-3797\(19\)30024-8/fulltext](https://www.ajpmonline.org/article/S0749-3797(19)30024-8/fulltext).
- Roditis M, Halpern-Felsher B. Adolescents' perceptions of risks and benefits of conventional cigarettes, e-cigarettes, and marijuana: a qualitative analysis. *Journal of Adolescent Health* 2015 August; 57(2): p. 179-185. doi:10.1016/j.jadohealth.2015.04.002.
53. [https://www.jahonline.org/article/S1054-139X\(15\)00157-3/fulltext](https://www.jahonline.org/article/S1054-139X(15)00157-3/fulltext).
54. McKelvey K, Halpern-Felsher B. Adolescent cigarette-smoking perceptions and behavior: Tobacco control gains and gaps amidst the rapidly expanding tobacco products market from 2001 to 2015. *Journal of Adolescent Health* 2017 February; 60(2): p. 226-228. doi: 10.1016/j.jadohealth.2016.09.025. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270372/>.
55. McKelvey K, Balocchi M, Halpern-Felsher B. Adolescents' and young adults' use and perceptions of pod-based electronic cigarettes. *JAMA Network Open* 2018 Oct 19; 1(6): p. e183535. doi:10.1001/jamanetworkopen.2018.3535. <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2707425>.
56. World Health Organization. WHO Report on the Global Tobacco Epidemic. [Online]. Geneva; 2019. Available from: <https://apps.who.int/iris/bitstream/handle/10665/326043/9789241516204-eng.pdf?ua=1> .
57. Hajek P, Phillips-Waller A, Przulj D, Pesola F, Myers Smith K, Bisal N. A randomized trial of e-cigarettes versus nicotine-replacement therapy. *New England Journal of Medicine* 2019 Jan 30. doi: 10.1056/NEJMoa1808779. <https://www.nejm.org/doi/full/10.1056/NEJMoa1808779>.
58. Indian Council of Medical Research. White Paper on Electronic Nicotine Delivery System. *Indian Journal of Medical Research*. 2019; 5(May): p. 574-583. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702703/>.

59. Worku D, Worku E. A narrative review evaluating the safety and efficacy of e-cigarettes as a newly marketed smoking cessation tool. *Sage Open Medicine*. 2019; 7(August). <https://journals.sagepub.com/doi/full/10.1177/2050312119871405>.
60. McAlinden KD, Sohal S, Sharma P. There can be smoke without fire: warranted caution in promoting electronic cigarettes and heat not burn devices as a safer alternative to cigarette smoking. *ERJ Open Research*. 2019; 5(Jul). <https://openres.ersjournals.com/content/5/3/00114-2019>.
61. Wallace A, Foronjy R. Electronic cigarettes: not evidence-based cessation. *Translational Lung Cancer Research*. 2019 ; 8 (Suppl 1)(May): p. S7-S10. <http://tlcr.amegroups.com/article/view/27956>.
62. Berenbaum E, Keller-Olaman S, Manson H, Moloughney B, Muir S, Simms C, et al. Current evidence on e-cigarettes: a summary of potential impacts. [Online]; 2018. Available from : <https://www.publichealthontario.ca/-/media/documents/literature-review-ecigarettes.pdf?la=en>.
63. Ontario Tobacco Research Unit. E-Cigarette use for smoking cessation: Scientific evidence and smokers' experiences. [Online]; 2019. Available from: https://www.otru.org/wp-content/uploads/2019/02/special_vape_quit.pdf.
64. Zawertailo L, Pavlov D, Ivanaova A, Ng G, Baaliunas D, Selby P. Concurrent e-cigarette use during tobacco dependence treatment in primary care settings: Association with smoking cessation at three and six months. *Nicotine and Tobacco Research* 2017: p. 183-189. doi:10.1093/ntr/ntw218. <https://academic.oup.com/ntr/article-abstract/19/2/183/2631714?redirectedFrom=fulltext>.
65. Glantz S. UCSF Stan Glantz blog. [Online].; 2018 [cited 2019 05 08. Available from: <https://tobacco.ucsf.edu/another-well-done-longitudinal-study-shows-e-cigs-depress-smoking-cessation>.
66. Callard C. Do e-cigarettes beat NRT as cessation aids? A key study provides two opposing results - yet only one was reported. [Online]; 2019 [cited 2019 10 23. Available from: <http://smoke-free-canada.blogspot.com/2019/10/do-e-cigarettes-beat-nrt-as-cessation.html>.
67. U.S. Centers for Disease Control and Prevention. Electronic Cigarettes. [Online]; 2019 [cited 2019 November 2. Available from: https://www.cdc.gov/tobacco/basic_information/e-cigarettes/index.htm.